“Since Democratic candidate Hillary Clinton vowed to control the rise of drug prices in the pharmaceutical space, investors have been expecting the sector to be impacted by the presidential election in November. Trump has also voiced concerns about drug prices. However, Larry McDonald, managing director at ACG Analytics, said Trump could help this group of stocks,” reports CNBC.
Related: Hit The Lab With These 17 Biotech ETFs
IBB, which holds nearly 190 stocks and is a cap-weighted ETF, has a price-to-earnings ratio of just over 21 and a price-to-book ratio of 4.92. The ETF’s three-year standard deviation is just over 25 percent.
“Biotechs have been hammered over the last year or so, because of some of Hillary Clinton’s comments, so a Trump presidency is bullish for the biotechs,” said McDonald in a CNBC interview.
iShares Nasdaq Biotechnology ETF
